Enhanced Conversion of DNA Radical Damage to Double Strand Breaks by 1,2,4-Benzotriazine 1,4-Dioxides Linked to a DNA Binder Compared to Tirapazamine

Chemical Research in Toxicology

Volumn 16, Issue 11, 2003, Pages 1477-1483

  Anderson, Robert F ^a,b   Harris, Tracy A ^a   Hay, Michael P ^b   Denny, William A ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; 3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; DOUBLE STRANDED DNA; HYDROXYL RADICAL; SINGLE STRANDED DNA; TIRAPAZAMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG DNA BINDING; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; GENE TARGETING; HUMAN; HYPOXIA; REDUCTION;

ACRIDINES; ANIMALS; ANOXIA; BINDING SITES; DNA; DNA ADDUCTS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; FREE RADICAL SCAVENGERS; FREE RADICALS; HYDROXYL RADICAL; PLASMIDS; PULSE RADIOLYSIS; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; WATER;

EID: 0344420319     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034116v     Document Type: Article

References (38)

1. Lee, D. J., Trotti, A., Spencer, S., Rostock, R., Fisher, C., von Roemeling, R., Harvey, E., and Groves, E. (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int. J. Radiat. Oncol. Biol. Phys. 42, 811-815.
2. Del Rowe, J., Scott, C., Werner-Wasik, M., Bahary, J. P., Curran, W. J., Urtasun, R. C., and Fisher, B. (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 18, 1254-1259.
3. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P. T., D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced nonsmall-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J. Clin. Oncol. 18, 1351-1359.
4. Brown, J. M., and Wang, L. H. (1998) Tirapazamine: laboratory data relevant to clinical activity. Anti-Cancer Drug Des. 13, 529-539.
5. Walton, M. I., and Workman, P. (1990) Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem. Pharmacol. 39, 1735-1742.
6. Walton, M. I., Wolf, C. R., and Workman, P. (1992) The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol. 44, 251-259.
7. Fitzsimmons, S. A., Lewis, A. D., Riley, R. J., and Workman, P. (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH: cytochrome P450 oxidoreductase. Carcinogenesis 15, 1503-1510.
8. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer 72, 1144-1150.
9. Patterson, A. V., Saunders, M. P., Chinje, E. C., Patterson, L. H., and Stratford, I. J. (1998) Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Des. 13, 541-573.
10. Laderoute, K., Wardman, P., and Rauth, A. M. (1988) Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem. Pharmacol. 37, 1487-1495.
11. Tuttle, S. W., Hazard, L., Koch, C. J., Mitchell, J. B., Coleman, C. N., and Biaglow, J. E. (1994) Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: Role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air. Int J. Radiat. Oncol. Biol. Phys. 29, 357-362.
12. Elwell, J. H., Siim, B. G., Evans, J. W., and Brown, J. M. (1997) Adaptation of human cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem. Pharmacol. 54, 249-257.
13. Baker, M. A., Zeman, E. M., Hirst, V. K., and Brown, J. M. (1988) Metabolism of SR 4233 by chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48, 5947-5952.
14. Teicher, B. A., Liu, J. T., Holden, S. A., and Herman, T. S. (1993) A carbonic-anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 13, 1549-1556.
15. Lloyd, R. V., Duling, D. R., Rumyantseva, G. V., Mason, R. P., and Bridson, P. K. (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol. Pharmacol. 40, 440-445.
16. Brown, J. M. (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67, 1163-1170.
17. Daniels, J. S., and Gates, K. S. (1996) DNA cleavage by the anti-tumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 118, 3380-3385.
18. Patterson, L. H., and Taiwo, F. A. (2000) Electron paramagnetic resonance spectrometry evidence for bioreduction of tirapazamine to oxidising free radicals under anaerobic conditions. Biochem. Pharmacol. 60, 1933-1935.
19. Anderson, R. F., Shinde, S. S., Hay, M. P., Gamage, S. A., and Denny, W. A. (2003) Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 125, 748-756.
20. Jones, G. D. D., and Weinfeld, M. (1996) Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res. 56, 1584-1590.
21. Daniels, J. S., Gates, K. S., Tronche, C., and Greenberg, M. M. (1998) Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 11, 1254-1257.
22. Hwang, J.-T., Greenberg, M. M., Fuchs, T., and Gates, K. S. (1999) Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 38, 14248-14255.
23. von Sonntag, C. The Chemical Basis of Radiation Biology; Taylor & Francis Ltd.: London, 1987.
24. Delahoussaye, Y. M., Hay, M. P., Pruijn, F. B., Denny, W. A., and Brown, J. M. (2003) Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol. 65, 1807-1815.
25. Evans, J. W., Yudoh, K., Delahoussaye, Y. M., and Brown, J. M. (1998) Tirapazamine is metabolised to its DNA damaging radical by intranuclear enzymes. Cancer Res. 58, 2098-2101.
26. Wardman, P. (1989) Reduction potentials of one-electron couples involving free radicals in aqueous solution. J. Phys. Chem. Ref. Data 18, 1637-1755.
27. Anderson, R. F., Amarasinghe, C., Fisher, L. J., Mak, W. B., and Packer, J. E. (2000) Reduction in free-radical-induced DNA strand breaks and base damage through fast chemical repair by flavonoids. Free Radical Res. 33, 91-103.
28. Siddiqi, M. A., and Bothe, E. (1987) Single- and double-strand break formation in DNA irradiated in aqueous solution: Dependence on dose and OH radical scavenger concentration. Radiat. Res. 112, 449-463.
29. Hodgkins, P. S., Fairman, M. P., and O'Neill, P. (1996) Rejoining of gamma-radiation-induced single-strand breaks in plasmid DNA by human cell extracts: dependence on the concentration of the hydroxyl radical scavenger, Tris. Radiat. Res. 145, 24-30.
30. Roberts, P. B., Denny, W. A., Wakelin, L. P. G., Anderson, R. F., and Wilson, W. R. (1990) Radiosensitization of mammalian cells in vitro by nitroacridines. Radiat. Res. 123, 153-164.
31. Nakashima, M., and Hayon, E. (1970) Rates of reaction of inorganic phoshate radicals in solution. J. Phys. Chem. 74, 3290-3291.
32. Biedermann, K, A., Wang, J., Graham, R. P., and Brown, J. M. (1991) SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer 63, 358-362.
33. Priyadarsini, K. I., Dennis, M. F., Naylor, M. A., Stratford, M. R. L., and Wardman, P. (1996) Free radical intermediates in the reduction of quinoxaline N-oxide antitumor drugs: redox and prototropic reactions. J. Am. Chem. Soc. 118, 5648-5654.
34. Wardman, P. (1987) The mechanism of radiosensitization by electron-affinic compounds. Radiat. Phys. Chem. 30, 423-432.
35. Greenstock, C. L., and Whitehouse, R. P. (1985) Radiosensitizers as probes of DNA damage and cell killing. Int. J. Radiat. Biol. 48, 701-710.
36. Ban, F., Gauld, J. W., and Boyd, R. J. (2001) Modeling the action of an antitumor drug: A density functional theory study of the mechanism of tirapazamine. J. Am. Chem. Soc. 123, 7320-7325.
37. Hay, M. P., Gamage, S. A., Kovacs, M., Pruijn, F. B., Anderson, R. F., Patterson, A. V., Wilson, W. R., Brown, J. M., and Denny, W. A. (2003) Structure-activity relationships of 1,2,4-Benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 46, 169-182.
38. Priyadarsini, K. I., Tracy, M., and Wardman, P. (1996) The one-electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine): a hypoxia-selective bioreductive drug. Free. Radical Res. 25, 393-400.